HC Wainwright Reiterates Buy Rating on AgomAb Therapeutics NV
HC Wainwright maintains a buy rating for AgomAb Therapeutics NV with a $35 price target, a 176.03% upside from the current price.
Key Points
- HC Wainwright reiterated its buy rating for AgomAb Therapeutics NV (AGMB) with a $35 price target on June 22, 2026.
- HC Wainwright's $35 price target implies 176.03% upside from AgomAb Therapeutics NV's ($AGMB) current $12.68 share price.
- Shares of AgomAb Therapeutics traded near $10.98 on Tuesday, with a market cap of about $583 million and a 52-week range from $8.75 to $17.45.
- TCG Crossover Management opened a new position in AgomAb Therapeutics, acquiring over 2 million shares valued at approximately $21.5 million.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 22, 2026, HC Wainwright reiterated its buy rating for AgomAb Therapeutics NV (NasdaqGS: AGMB) with a price target of $35. The analyst behind this rating is Patrick R. Trucchio, who continues to see potential in the company's future performance.
HC Wainwright & Co. vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in AgomAb Therapeutics
TCG Crossover Management, LLC opened a new position in AgomAb Therapeutics, acquiring 2,053,233 shares. This new stake is valued at approximately $21.5 million, signaling a significant interest in the company's prospects.
AgomAb Therapeutics NV Stock Down 3.7%
Shares of NasdaqGS:AGMB traded near $10.98 on Tuesday. AgomAb Therapeutics has a market cap of about $583 million. The stock has traded between $8.75 and $17.45 over the past 52 weeks. It has a 50-day moving average of $10.98 and a 200-day moving average of $12.25. The company maintains a strong liquidity position with a current ratio of 6.52 and a quick ratio of 6.49, but it is not currently profitable, showing a forward P/E ratio that is not meaningful.
$AGMB price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Analysts Set New Price Targets
On June 22, 2026, HC Wainwright & Co. reiterated its rating for AgomAb Therapeutics with a buy rating and set a $35 price target. Earlier this year, on March 3, 2026, Leerink Partners, JP Morgan, and Morgan Stanley all initiated coverage with buy ratings, setting price targets at $36, $32, and $28, respectively. The consensus among analysts suggests a mean price target of $32, with three analysts offering opinions.
About AgomAb Therapeutics NV
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company based in Antwerp, Belgium. It develops innovative therapies for immunology and inflammatory diseases. The company's pipeline includes Ontunisertib, a treatment for Fibrostenosing Crohn's disease, and AGMB-447 for idiopathic pulmonary fibrosis. Founded in 2017, AgomAb is led by CEO Dr. Tim Knotnerus and employs 62 people.
Bottom Line
AgomAb Therapeutics NV continues to attract attention from analysts and investors alike, with HC Wainwright reaffirming its buy rating and a $35 target. The company's innovative approach in developing treatments for complex diseases makes it a noteworthy player in the biotechnology sector. As always, 13F filings and analyst ratings are backward-looking and may not represent the most current positions or opinions.
Get AgomAb Therapeutics NV alerts
New 13F filings, insider trades, and analyst moves on $AGMB, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.